╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╕
│ Personal Criteria                                  │ CHIA Criteria                                      │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╡
│ Subjects who have received any HDAC inhibitors     │ Subjects who have received any HDAC inhibitors     │
│ other than valproic acid                           │ other than valproic acid                           │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ History of malignancy                              │ No Match                                           │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Must agree not to donate blood or other bodily     │ Must agree not to donate blood or other bodily     │
│ fluid while taking the study drug and for 28 days  │ fluid while taking the study drug and for 28 days  │
│ thereafter                                         │ thereafter                                         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Known positive status for HIV, active hepatitis B  │ Known positive status for HIV, active hepatitis B  │
│ or hepatitis C                                     │ or hepatitis C                                     │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Need for chronic narcotic medications for pain     │ No Match                                           │
│ from sickle cell disease                           │                                                    │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Subjects with unresolved infections                │ Subjects with unresolved infections                │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Subjects who have received RBC transfusions cannot │ Subjects who have received RBC transfusions cannot │
│ have >15% adult hemoglobin                         │ have >15% adult hemoglobin                         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Known allergic reaction to a histone deacetylase   │ Known allergic reaction to a histone deacetylase   │
│ inhibitor                                          │ inhibitor                                          │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Non-hematologic laboratory values as outlined in   │ Non-hematologic laboratory values as outlined in   │
│ the protocol                                       │ the protocol                                       │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Women of child-bearing potential and men must      │ Women of child-bearing potential and men must      │
│ agree to use 2 forms of adequate contraception     │ agree to use 2 forms of adequate contraception     │
│ prior to study entry and for the duration of study │ prior to study entry and for the duration of study │
│ participation                                      │ participation                                      │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ History of multi-organ failure                     │ No Match                                           │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Subjects on fetal hemoglobin inducing agents       │ Subjects on fetal hemoglobin inducing agents       │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ History of avascular necrosis                      │ No Match                                           │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ 18 years of age or older                           │ 18 years of age or older                           │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Women of child-bearing potential (WCBP) must have  │ Women of child-bearing potential (WCBP) must have  │
│ a negative serum pregnancy test 72 hours or less   │ a negative serum pregnancy test 72 hours or less   │
│ prior to starting treatment                        │ prior to starting treatment                        │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ History of priapism                                │ No Match                                           │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Historically disease-free for at least 5 years     │ No Match                                           │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Failed a previous attempt at treatment with        │ No Match                                           │
│ hydroxyurea                                        │                                                    │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Diagnosed and adequately treated within the past 5 │ No Match                                           │
│ years                                              │                                                    │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Pregnant or breast feeding women                   │ Pregnant or breast feeding women                   │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Deemed by the investigator to be at low risk for   │ No Match                                           │
│ recurrence of malignancy                           │                                                    │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Contraindications to hydroxyurea                   │ No Match                                           │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Subjects with a history of thrombosis or other     │ Subjects with a history of thrombosis or other     │
│ reason (other than sickle cell disease) for        │ reason (other than sickle cell disease) for        │
│ enhanced thrombotic risk                           │ enhanced thrombotic risk                           │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Subjects on any other experimental treatment       │ Subjects on any other experimental treatment       │
│ within 90 days of the first dose of study drug or  │ within 90 days of the first dose of study drug or  │
│ who have not recovered from the side effects of    │ who have not recovered from the side effects of    │
│ such therapy                                       │ such therapy                                       │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Diagnosis of sickle cell disease                   │ Diagnosis of sickle cell disease                   │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ History of stroke                                  │ No Match                                           │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Must have minimum age of 18 Years                  │ No Match                                           │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Subjects with hemoglobin SC or SB+ thalassemia     │ Subjects with hemoglobin SC or SB+ thalassemia     │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Severe or uncontrolled medical conditions that     │ Severe or uncontrolled medical conditions that     │
│ could compromise study participation               │ could compromise study participation               │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Subjects who have received valproic acid for       │ Subjects who have received valproic acid for       │
│ treatment of epilepsy within 30 days of enrollment │ treatment of epilepsy within 30 days of enrollment │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ History of acute chest syndrome                    │ No Match                                           │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ At least 1 painful episode per year averaged over  │ No Match                                           │
│ the previous 3 years                               │                                                    │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Inability to tolerate hydroxyurea treatment due to │ No Match                                           │
│ severe side effects                                │                                                    │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Hematologic laboratory values as outlined in the   │ Hematologic laboratory values as outlined in the   │
│ protocol                                           │ protocol                                           │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Subjects on chronic transfusion program            │ Subjects on chronic transfusion program            │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╛